Xeljanz and Xeljanz XR are Janus kinase (JAK) inhibitors indicated to treat moderately to severely active rheumatoid arthritis when methotrexate therapy is inadequate.
ACR/ARHP 2016 Annual Meeting
Statistically significant improvements were shown 3 months vs. placebo with tofacitinib, in this new study
ACR/ARHP Annual Meeting 2015
According to study results presented at the 2015 ACR/ARHP Annual Meeting, initiating non-TNF inhibitor monotherapy had similar or better efficacy compared with initiation of TNF inhibitor monotherapy in patients with rheumatoid arthritis.